Investigation of HER-2 Expression and Its Correlation with Clinicopathological Parameters and Overall Survival of Esophageal Squamous Cell Carcinoma Patients

Mitra Heidarpour¹, Mehran Taheri¹, Ali Akhavan², Parvin Goli³, Amirhosein Kefayat⁴*

1. Department of Pathology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
2. Department of Radiation Oncology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
3. Department of Immunology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
4. Department of Oncology, Cancer Prevention Research Center, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

KEYWORDS

Esophageal cancer, Human epidermal growth factor receptor 2, Squamous cell carcinoma

ABSTRACT

Background & Objective: Human epidermal growth factor receptor 2 (HER-2) exhibits a vast range of expression in esophageal squamous cell carcinoma (ESCC) patients as a biomarker. This paper aimed to investigate HER-2 expression and clinicopathological parameters of esophageal SCC.

Methods: HER-2 expression was assessed in 102 ESCC patients by immunohistochemistry. The HER-2 staining intensity, according to the Gastric HER2 Biomarker1.0.0.1 version of the college of American pathologists (CAP) protocol for gastric and gastroesophageal junction cancers, was graded as 0 (no reactivity in any of the cancer cells’ membranes); 1+ (pale or hardly noticeable reaction in the membrane of cancer cells’ cluster [≥ 5 neoplastic cells] regardless of the positive cancer cells’ percentage); 2+ (weak-to-moderate complete, basolateral, or lateral membranous reactivity regardless of the positive cancer cells’ percentage); and 3+ (strong complete, basolateral, or lateral reactivity in the membrane of the cancer cell cluster regardless of the positive cancer cells’ percentage). In this regard, 3+ scored samples were considered as positive. If HER-2 expression was scored 2+, an additional fluorescence in situ hybridization (FISH) was performed. Fisher’s exact test was employed for investigating the correlation of HER-2 expression status with patients’ clinicopathological characteristics (including age, gender, tumor location, stage, grade, infiltration level, venous invasion, lymphatic invasion, and tumor recurrence). Kaplan-Meier analysis was done for the patients’ survival assessments.

Results: Five patients (~5%) were HER-2 positive and no significant association was observed between HER-2 expression and clinicopathological properties. In addition, HER-2 expression status exhibited no significant association with the patients’ overall survival (P=0.9299).

Conclusion: HER-2 is not a suitable prognostic biomarker for Iranian ESCC patients.

Introduction

Esophageal cancer has become a major public health problem in the world. According to statistical analyses, it is the sixth most common cancer worldwide and the ninth most common cause of cancer-related deaths (1). Squamous cell carcinoma (SCC) is the most frequent histological type of esophagus cancer (2). Environmental factors play a determinative role in the rising of these tumors (3). Despite intensive therapeutic interventions, including surgical resection with lymphadenectomy and different pre- and post-operation adjuvant therapies, most of the patients with the localized disease develop metastatic lesions, and the mortality rate is still high (4). Esophageal squamous cell carcinoma (ESCC) generally exhibits a poor prognosis due to its advanced stage at the time of diagnosis, and the survival rates of patients with advanced disease are not satisfactory (5).

Human epidermal growth factor receptor 1 (HER-1), HER-2, HER-3, and HER-4 are the four homologs members of the HER family. Abnormal kinase activity in these receptors can cause ESCC tumor development, progression, and even metastasis (6). Their determinative role was demonstrated in breast cancer...
and led to the appearance of specific treatments based on inhibition and inactivation of these receptors (7). HER-2 proto-oncogene is a 185-kDa transmembrane glycoprotein with tyrosine-specific kinase activity (8). Its gene (HER-2/neu) locates on chromosome 17 (17q12–q21.32) (9). HER-2 expression is detected in 22–66% of ovarian cancer patients (10). Also, its expression was detected in 26% of gastric cancers (11).

Monoclonal antibody (mAb), with a high ability of attaching to HER-2 receptor (Herceptin®), causes anti-growth effects against HER-2 overexpressing tumors. Herceptin has attracted lots of clinicians’ attention in immunotherapy, and it is the first approved mAb for the treatment of breast cancer (12). Besides, multiple pre-clinical and clinical studies have reported that HER-2 can be immunogenic. Antibody generation and cytotoxic T lymphocytes and T helper cells’ activation against HER-2 positive cells were observed in individuals with HER-2 overexpressing tumors (13–15). Therefore, anti-HER-2 immune therapy could be utilized as a suitable therapeutic approach for cancers such as esophageal cancer. However, a vast spectrum of the HER-2 expression rate was reported for ESCC (16–18). Therefore, it is vital to determine the HER-2 expression frequency in the target population to determine the possibility of HER-2 based immunotherapy.

To the best of our knowledge, a vast spectrum of HER-2 expression in ESCC was reported by different studies. In addition, a limited number of studies have reported the correlation of HER-2 expression with clinicopathological parameters of ESCC patients, especially in Iranian patients. This study aimed to investigate the frequency of HER-2 expression and its correlation with the clinicopathologic properties of Iranian ESCC patients.

### Materials and Methods

#### Patients and Samples

This retrospective study was conducted at the Pathology Department of Isfahan University of Medical Sciences. This study was carried out on 102 paraffin-embedded samples, obtained from the archive of the Pathology Department, Al-Zahra Hospital. All specimens belonged to the ESCC patients, who were diagnosed and undergone surgery from January 2012 to December 2017. Patients with intact and complete clinical data (including diagnosis, age, sex, address, disease history, and pathological reports) were just included in this study. In this regard, patients who were diagnosed with other malignancies of the esophagus or diagnosed with other malignancies of the esophagus or gastroesophageal junction cancers, was graded as 2+ (moderate complete, basolateral, or lateral membranous reactivity regardless of the positive cancer cells’ percentage); and 3+ (strong complete, basolateral, or lateral reactivity in the membrane of the cancer cell cluster regardless of the positive cancer cells’ percentage). If HER-2 expression was scored 2+, an additional fluorescence in situ hybridization (FISH) was performed according to previous studies to confirm positivity (17).

#### Immunohistochemistry

For immune staining, 3–5 mm sections of the paraffin-embedded specimens were prepared. The samples were incubated at 60°C (40 min) and immersed in xylene (Sigma, USA) for deparaffinization. Subsequently, the samples were placed in the decreasing ethanol solutions for rehydration and deactivation of endogenous peroxidases; the samples were incubated in 0.3% hydrogen peroxide. Then, phosphate buffer saline (PBS) was used for washing the slides (Sigma, USA), and the washed slides were heated in an 830-W microwave oven for at least 15 min in 10 mmol/L sodium citrate buffer (pH 6.0) (Sigma-Aldrich, Germany) for antigen retrieval.

The slides were incubated with mouse anti-HER-2 monoclonal antibody (Clone SP107, Master Diagnostica, Spain) overnight at 4°C. Also, PBS was replaced by the primary antibody in some samples to have negative controls. The rabbit anti-mouse horseradish peroxidase-conjugated secondary antibody (Abcam, USA) was incubated for 40 min at room temperature. Then, the diaminobenzidine (DAB) (Sigma-Aldrich, Germany) was used as a chromogen. After each step, the slides were washed three times by PBS.

#### Immunostaining Scoring

The immunostained sections were observed under a light microscope (Olympus, Japan) by two pathologists, who were not aware of the patients’ clinicopathological data. A double-headed microscope was used for the simultaneous assessment of the samples if there were any discrepancies between the pathologists’ reports. In this study, the HER-2 scoring was based on the Gastric HER2 Biomarker 1.0.0.1 version of the college of American pathologists (CAP) protocol for gastric and gastroesophageal junction cancers (21). The intensity of HER-2 staining, according to the CAP protocol for gastric and gastroesophageal junction cancers, was graded as follows: 0 (no reactivity in any of the cancer cells’ membranes), 1+ (pale or hardly noticeable reactivity in the membrane of cancer cells’ cluster [≥ 5 neoplastic cells] regardless of the positive cancer cells’ percentage); 2+ (weak-to-moderate complete, basolateral, or lateral membranous reactivity regardless of the positive cancer cells’ percentage); and 3+ (strong complete, basolateral, or lateral reactivity in the membrane of the cancer cell cluster regardless of the positive cancer cells’ percentage). If HER-2 expression was scored 2+, an additional fluorescence in situ hybridization (FISH) was performed according to previous studies to confirm positivity (17).

#### Statistical Analysis

JMP software version 11.0 (SAS institute, Japan) was employed for statistical analyzes. The correlation of HER-2 expression and clinicopathological parameters was assessed by Fisher’s exact test. Patients’ overall survival was calculated by using the
Kaplan–Meier method and compared by the log-rank test. A P-value<0.05 was considered significant.

Results

HER-2 Expression in ESCC Patients

A total of 102 ESCC patients were investigated in this study. Their clinicopathological parameters are illustrated in Table 1. The patients’ age ranged from 36 to 86 years old, and their median was 62. Further, 64% of the patients were male. More than half of the tumors were located in the middle portion of the esophagus, and the most common infiltration level (T) was T3. About 28% and 34% of the patients were positive for venous and lymph node invasion, respectively. Also, 52% of the patients exhibited tumor recurrence.

Table 1. Clinicopathological characteristics of the ESCC patients.

| Clinicopathological parameters | Patients number (n=102) | Proportion (%) |
|-------------------------------|------------------------|----------------|
| Age Median                    | 62 [36-86]             |                |
| Gender                        |                        |                |
| Male                          | 65                     | 64%            |
| Female                        | 37                     | 36%            |
| Tumor location                |                        |                |
| Upper                         | 17                     | 17%            |
| Middle                        | 53                     | 52%            |
| Lower                         | 32                     | 31%            |
| T                             |                        |                |
| T1                            | 15                     | 15%            |
| T2                            | 22                     | 21%            |
| T3                            | 55                     | 54%            |
| T4                            | 10                     | 10%            |
| Nodal status                  |                        |                |
| N0                            | 61                     | 60%            |
| N1                            | 26                     | 25%            |
| N2                            | 10                     | 10%            |
| N3                            | 5                      | 5%             |
| Grade                         |                        |                |
| G1                            | 31                     | 30%            |
| G2                            | 56                     | 55%            |
| G3                            | 15                     | 15%            |
| Stage                         |                        |                |
| I                             | 14                     | 14%            |
| II                            | 49                     | 48%            |
| III                           | 19                     | 18%            |
| IV                            | 20                     | 20%            |
| Venous invasion               |                        |                |
| Negative                      | 74                     | 73%            |
| Positive                      | 28                     | 27%            |
| Lymphatic invasion            |                        |                |
| Negative                      | 68                     | 67%            |
| Positive                      | 34                     | 33%            |
Correlation of HER-2 Expression with Clinicopathological Parameters of ESCC Patients

The patients were divided into two groups based on the HER-2 expression status (Table 2). A limited number of patients (n=5) were HER-2 positive, according to the utilized scoring method. As illustrated in Table 2, no significant ($P>0.05$) correlation was observed between HER-2 expression and clinicopathological parameters, including age ($P=0.3525$), gender ($P=0.2524$), histological grade ($P=0.3617$), infiltration level ($P=0.5784$), lymph node status ($P=0.9927$), venous ($P=0.6929$) and lymphatic invasion ($P=0.7491$), and tumor recurrence ($P=0.4577$). In this study, a few percentages of the patients were HER-2 positive, and this expression status did not exhibit a significant correlation with their clinicopathological properties.

Table 2. Clinicopathological parameters of the ESCC patients in the HER-2 positive and negative patients.

| Clinicopathological parameters | HER-2-negative [n=97] | HER-2-positive [n=5] | P-value |
|--------------------------------|-----------------------|----------------------|---------|
| **Age**                        |                       |                      |         |
| ≤ 60 years                     | 56 (58%)              | 3 (60%)              | 0.3525  |
| > 60 years                     | 41 (42%)              | 2 (40%)              |         |
| **Gender**                     |                       |                      |         |
| Male                           | 62 (64%)              | 3 (60%)              | 0.2524  |
| Female                         | 35 (36%)              | 2 (40%)              |         |
| **Tumor location**             |                       |                      |         |
| Upper                          | 30 (15%)              | 2 (40%)              | 0.2584  |
| Middle                         | 52 (54%)              | 1 (20%)              |         |
| Lower                          | 15 (31%)              | 2 (40%)              |         |
| **T**                          |                       |                      |         |
| T1                             | 14 (14%)              | 1 (20%)              | 0.5784  |
| T2                             | 20 (21%)              | 2 (40%)              |         |
| T3                             | 53 (55%)              | 2 (40%)              |         |
| T4                             | 10 (10%)              | 0 (0%)               |         |
| **Nodal status**               |                       |                      |         |
| N0                             | 58 (60%)              | 3 (60%)              | 0.9927  |
| N1-3                           | 39 (40%)              | 2 (40%)              |         |
| **Grade**                      |                       |                      |         |
| G1                             | 30 (31%)              | 1 (20%)              | 0.3617  |
| G2                             | 54 (56%)              | 2 (40%)              |         |
| G3                             | 13 (13%)              | 2 (40%)              |         |
Clinicopathological parameters | HER-2-negative [n= 97] | HER-2-positive [n=5] | P-value
---|---|---|---
**Stage**
I | 14 (14%) | 0 (0%) | 0.6688
II | 46 (47%) | 3 (60%) | 
III | 18 (19%) | 1 (20%) | 
IV | 19 (20%) | 1 (20%) | 
**Venous invasion**
Negative | 70 (72%) | 4 (80%) | 0.6929
Positive | 27 (28%) | 1 (20%) | 
**Lymphatic invasion**
Negative | 65 (67%) | 3 (60%) | 0.7491
Positive | 32 (33%) | 2 (40%) | 
**Recurrence**
Negative | 37 (38%) | 3 (60%) | 0.4577
Positive | 51 (53%) | 2 (40%) | 
Data not available | 9 (9%) | 0 (0%) | 

**Predictive Value of HER-2 Expression Status for ESCC Patients’ Survival**

The correlation of HER-2 expression status and the patients’ survival were investigated within 24 months after diagnosis date by searching patients’ disease history. Kaplan-Meier survival analysis with a log-rank test was used for this purpose. As Figure 1 illustrates, the overall survival rates were up to 20% (1/5) and 30% (79/97) for the HER-2 positive and negative patients, respectively. Therefore, HER-2 expression status was not significantly correlated with ESCC patients’ overall survival (P=0.9299).

**Fig. 1.** The overall survival of patients in the HER-2 positive and negative groups within 24 months after diagnosis. (Log-Rank=0.0077, P=0.9299)

**Discussion**

The HER family plays a key role in epithelial cell growth, proliferation, and differentiation. Therefore, it would be a good choice for targeted therapy. HERs are transmembrane proteins with an extracellular domain for binding to the ligands and intracellular tyrosine kinase domain (22). A ligand binding to a single receptor induces conformational changes and dimerization, which activates the kinase activity of the intracellular domain and downstream signaling cascade. Among all four HER family proteins, HER-2 has the strongest activity (23).

Overamplification of this gene significantly affects tumors’ development. HER-2 amplification has been...
described in tissue samples from different malignancies, such as breast, gastric, and pancreatic cancers (24–27). Further investigation demonstrated the correlation of HER-2 overexpression and poor prognosis in ovarian and breast cancers (28,29). Amplification of the HER-2 antigen has been detected in 15–30% of invasive breast cancers (30). The wide range of expression reflects that HER-2 has a vast spectrum of expression rates in different populations. The frequency of HER-2 overexpression in ESCC has been reported to vary from 0% up to about 65%, according to immunohistochemistry (IHC) investigations (31–35).

In a report describing the HER-2 status in ESCC, HER-2 overexpression was correlated with extramural invasion and poor response to neoadjuvant chemotherapy (32). However, there is an apparent controversy regarding the expression of HER-2 receptor in esophageal carcinoma. Gibault et al. (36) and Reichelt et al. (37) observed positive expression of the HER-2 receptor in 28% and 7% of the involved ESCC patients in their studies, respectively. Nonetheless, some studies reported positive expression of the HER-2 marker in more than 50% of their included patients’ tumors (31). Multiple reasons can be mentioned for explaining these significant differences, including patient selection methods, immunostaining procedures, and scoring protocols.

Wu et al. (38) observed the HER-2 overexpression in 14.1% of the ESCC patients. Also, Yoon et al. (39) and Zhan et al. (33) reported about 17% and 10% of the HER-2 overexpression in the esophageal adenocarcinomas and ESCC tumors, respectively. In a study by Mimura et al., only 9 cases of 66 primary ESCC tumors were HER-2 positive. Three of these cases scored 3+, which exhibited HER-2 overexpression in the metastatic lymph nodes. The other six cases were 2+ score in the primary tumors; four cases had metastases, and only two out of four lymph node metastases retained 2+ HER-2 expression. The other two cases exhibited negative HER-2 staining (32).

Different studies have mentioned various conclusions regarding the correlation of HER-2 expression and clinicopathological parameters of ESCC patients. Wu et al. reported no significant correlation between the ESCC patients’ tumor HER-2 overexpression and their clinicopathological characteristics (38). On the other hand, Zhan et al. observed significant correlations between HER-2 expression status of tumors and their differentiation level and stage (33). According to a study at the Mayo Clinic, esophageal adenocarcinoma patients with positive HER-2 expression exhibited lower tumor aggressiveness and higher survival time (39). Another study identified low HER-2 amplification in ESCC patients and its correlation with tumor infiltration depth and vascular and lymph node metastases (40). However, Barros Silva reported that HER-2 amplification does not have a significant correlation with the gastric cancer patients’ age, gender, staging, or lymph node metastasis (41).

According to our study, which was carried out on 102 ESCC patients, a limited number of patients were HER-2-positive, which comprised 5% of the studied cases. However, there was no correlation between the HER-2 expression and the clinicopathological features. About 28% and 34% of the patients were positive for venous and lymph node invasion, respectively. Also, 52% of the patients exhibited tumor recurrence. However, no difference was observed between HER-2 positive and negative patients in these parameters.

Conclusion

The analysis of HER-2 expression exhibited a significantly lower number of HER-2 positive cases in the Iranian ESCC patients compared with previous studies in other populations. No correlation was observed between HER-2 status and age, gender, tumor location, infiltration level, stage, grade, lymph node status, venous, lymphatic invasion, and overall survival of the ESCC patients. Taking together, HER-2 is not an efficient prognostic biomarker and potential therapeutic target for Iranian ESCC patients. To confirm these findings, more comprehensive studies are needed.

Acknowledgements

This study was supported by Isfahan University of Medical Sciences (Grant number: 35705).

Conflict of Interest

The authors confirm that there are no known conflicts of interest associated with this publication, and there has been no significant financial support for this work that could have influenced its outcome.

References
1. Klingelhöfer D, Zhu Y, Braun M, Brügmann D, Schoffel N, Gromeberg DA. A world map of esophageus cancer research: a critical accounting. J Transl Med. 2019 Dec 1;17(1):150. [DOI:10.1186/s12967-019-1902-7] [PMID] [PMCID]
2. Vijayan K, Estlick GD. Epidemiology and Risk Factors for Esophageal Cancer. Esophageal Cancer: Springer; 2020. p. 1-32. [DOI:10.1007/978-3-030-29832-6_1] [PMID] [PMCID]
3. Dietz HC. TGF-β in the pathogenesis and prevention of disease: a matter of aneurysmic proportions. J Clin Invest. 2010 Feb 1;120(2):403-6. [DOI:10.1172/JCI42014] [PMID] [PMCID]
4. Ilson DH. Esophageal cancer chemotherapy: recent advances. Gastrointest Cancer Res. 2008 Mar;2(2):85.
5. Bird-Lieberman E, Fitzgerald RJBjoc. Early diagnosis of oesophageal cancer. 2009;101(1):1. [DOI:10.1038/sj.bjc.6605126] [PMID] [PMCID]
6. Matsuda N, Wang X, Lim B, Krishnamurthy S, Alvarez RH, Willey JS, Parker CA, Song J, Shen Y, Hu J, Wu W. Safety and efficacy of panitumumab plus neoadjuvant chemotherapy in patients with primary her2-negative inflammatory breast cancer. JAMA oncology. 2018 Sep 1;4(9):1207-13.
7. Roskoski Jr R. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun. 2004 Jun 18;319(1):1-1. [DOI:10.1016/j.bbrc.2004.04.150] [PMID] [PMCID]

8. Márquez-Garbán DC, Gorrín-Rivas M, Chen HW, Sterling Jr C, Elashoff D, Hamilton N, Pietras RJ. Squalamine blocks tumor-associated angiogenesis and growth of human breast cancer cells with or without HER-2/neu overexpression. Cancer Lett. 2019 May 1;449:66-75. [DOI:10.1016/j.canlet.2019.05.001] [PMID] [PMCID]

9. Genc AZ, Koseoglu RD, Arici A, Demir O. HER-2/neu gene analysis on endoscopic biopsy samples and gastric resection materials in gastric carcinomas. 2019. [DOI:10.15275/rusomj.2019.0410]

10. Chung YW, Kim S, Hong JH, Lee JK, Lee NW, Lee YS, Song JY. Overexpression of HER2/HER3 and clinical feature of ovarian cancer. Journal of gynecologic oncology. 2019 May 16;30(5). [DOI:10.3802/jgo.2019.30.e75] [PMID] [PMCID]

11. Raziei H, Taghizadeh Kermani A, Ghaffarzaedegan K, Taghi Shakeri M, Ghavamnasiri MJJoBMS. HER-2/neu Gene Overexpression in Resectable Gastric Cancer and its Relationship with Histopathologic Subtype, Grade, and Stage. 2007;10(2):139-45.

12. Sawyers CL, Hercep tin: A First Assault on Oncogenes that Launched a Revolution. Cell. 2019 Sep 19;179(1):8-12. [DOI:10.1016/j.cell.2019.08.027] [PMID] [PMCID]

13. Kuznetsova M, Lopatnikova J, Shevchenko J, Silkov A, Maksyutov A, Sennikov S. Cytotoxic activity and mempoT cell subset distribution of in vitro-stimulated CD8+ T cells specific for HER2/neu epitopes. Front Immunol. 2019 May 9;10:1017. [DOI:10.3389/fimmu.2019.01017] [PMID] [PMCID]

14. Yadav K, Shimasaki N, Ow SGW, Wong ALA, Lim JSJ, Koe P, et al. Tumor pathological and immunological changes in HER2+ metastatic breast cancer (MBC) following trastuzumab combined with expanded and activated autologous natural killer (NK) cell infusion. Am Soc Clin Oncol. 2019. [DOI:10.1200/JCO.2019.37.15_suppl.e12511]

15. Triulzi T, Forte L, Regondi V, Di Modica M, Ghirelli C, Carcangi ML, Sfondrini L, Balsari A, Tagliabue E. HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy. Oncoimmunology. 2019 Jan 2;8(1):e151942. [DOI:10.1080/2162402X.2018.151942] [PMID] [PMCID]

16. Gonzaga IM, Soares-Lima SC, de Santos PT, Blanco TC, de Reis BS, Quintella DC, de Oliveira IM, de Faria PA, Kruel CD, Andreollo NA, de Simão TA. Alterations in epithelial growth factor receptors 1 and 2 in esophageal squamous cell carcinomas. BMC cancer. 2012 Dec 1;12(1):569. [DOI:10.1186/1471-2407-12-569] [PMID] [PMCID]

17. Sato-Kuwabara Y, Neves JI, Frenagnani JH, Sallum RA, Soares FA. Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry. BMC cancer. 2009 Dec 1;9(1):6. [DOI:10.1186/1471-2407-9-6] [PMID] [PMCID]

18. Wei Q, Chen L, Sheng L, Nordgren H, Wester K, Carlsson J. EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases. Int J Oncol. 2007 Sep 1;31(3):493-9. [DOI:10.3892/ijo.31.3.493] [PMID] [PMCID]

19. Peng JH, Zhang X, Song JL, Ran L, Luo R, Li HY. Wang YH. Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma. Med. 2019 Jan;98(2). [DOI:10.1097/MJH.00000000000013554] [PMID] [PMCID]

20. Shu S, limori M, Nakanishi R, Jogo T, Saeki H, Oki E, Maehara Y. Changes in HER2 expression and amplification status following preoperative chemotherapy for gastric cancer. in vivo. 2018 Nov 1;32(6):1491-8. [DOI:10.21873/inivo.11405] [PMID] [PMCID]

21. Bartley AN, Jessi Christ C, Fitzgibbonbs P, Hamilton SR, Kakar S, Shah MA, et al. Template for Reporting Results of HER2 (ERBB2) Biomarker Testing of Specimens from Patients with Adenocarcinoma of the Stomach or Gastroesophageal Junction. 2017.

22. Roskoski Jr RJPr. The ErbB/HER family of protein-tyrosine kinases and cancer. 2014;79:34-74. [DOI:10.1016/j.phrs.2013.11.002] [PMID]

23. Cretella D. Combined use of tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs) as target therapy in non-small cell lung cancer (NSCLC) (Doctoral dissertation, Università di Parma, Dipartimento di Scienze Biomediche, Biotechnologie e Traslazionali).

24. Jørgensen JT, Nielsen KB, Kjærgaard G, Jepsen A, Møllerup J. Gene signal distribution and HER2 amplification in gastroesophageal cancer. J Cancer. 2017;8(9):1517. [DOI:10.7159/jca.17878] [PMID] [PMCID]

25. Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, Ji X, Liu W, Huang B, Luo W, Liu B. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 2018 Jun 1;5(2):77-106. [DOI:10.1016/j.gendis.2018.05.001] [PMID] [PMCID]

26. Liu Q, Borcherding NC, Shao P, Maina PK, Zhang W, Qi HH. Contribution of synergism between PHF8 and HER2 signalling to breast cancer development and drug resistance. EBioMedicine. 2020 Jan 1;51:102612. [DOI:10.1016/j.ebiom.2019.102612] [PMID] [PMCID]

27. Shibata W, Kinoshita H, Hikiba Y, Sato T, Ishii Y, Sue S, Sugimori M, Suzuki N, Sakitani K, Iijchi H, Mori R. Overexpression of HER2 in the pancreas promotes intraductal papillary mucinous neoplasms in mice. Sci Reports. 2018 Apr 18;8(1):1-0. [DOI:10.1038/s41598-018-24375-2] [PMID] [PMCID]

28. Lei YY, Huang JY, Zhao QR, Jiang N, Xu HM, Wang ZN, Li HQ, Zhang SB, Sun Z. The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature. World J Surg Oncol. 2017 Dec;15(1):1-
7. [DOI:10.1186/s12957-017-1132-5] [PMID] [PMCID]
29. Luo H, Xu X, Ye M, Sheng B, Zhu X. The prognostic value of HER2 in ovarian cancer: a meta-analysis of observational studies. PloS one. 2018 Jan 30;13(1):e0191972. [DOI:10.1371/journal.pone.0191972] [PMID] [PMCID]
30. Iqbal N, Iqbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Molec Biol Int. 2014;2014. [DOI:10.1155/2014/852748] [PMID] [PMCID]
31. Akamatsu M, Matsumoto T, Oka K, Yamasaki S, Sonoue H, Kajiyama Y, Tsurumaru M, Sasai K. c-erbB-2 oncoprotein expression related to chemoradioreistance in esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1323-7. [DOI:10.1016/S0360-3016(03)00782-X]
32. Mimura K, Kono K, Hanawa M, Mitsui F, Sugai H, Miyagawa N, Ooi A, Fujii H. Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. Br J Cancer. 2005 Apr;92(7):1253-60. [DOI:10.1038/sj.bjc.6602499] [PMID] [PMCID]
33. Zhan N, Dong WG, Tang YF, Wang ZS, Xiong CL. Analysis of HER2 gene amplification and protein expression in esophageal squamous cell carcinoma. Med Oncol. 2012 Jun 1;29(2):933-40. [DOI:10.1007/s12032-011-9850-x] [PMID]
34. Schoppmann SF, Jesch B, Friedrich J, Wrba F, Schultheis A, Pluschnig U, Maresch J, Zacherl J, Hejna M, Birner P. Expression of Her-2 in carcinomas of the esophagus. Am J Surg Pathol. 2010 Dec 1;34(12):1868-73. [DOI:10.1097/PAS.0b013e3181f8be17] [PMID]
35. Maruyama T, Mimura K, Sato E, Watanabe M, Mizukami Y, Kawaguchi Y, Ando T, Kinouchi H, Fujii H, Kono K. Inverse correlation of HER2 with MHC class I expression on oesophageal squamous cell carcinoma. Br J Cancer. 2010 Aug;103(4):552-9. [DOI:10.1038/sj.bjc.6605772] [PMID] [PMCID]
36. Gibault L, Metges JP, Conen-Charlet V, Lozač’h P, Robaszkiewicz M, Bessauguet C, Lagarde N, Volant A. Diffuse EGFR staining is associated with reduced overall survival of esophageal squamous cell cancer. Br J Cancer. 2005 Jul;93(1):107-15. [DOI:10.1038/sj.bjc.6602625] [PMID] [PMCID]
37. Reichelt U, Duesedau P, Tsourlakis MC, Quaa A, Link BC, Schurt PG, Kaifi JT, Gros SJ, Yekebas EF, Marx A, Simon R. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Modern Pathol. 2007 Jan;20(1):20-9. [DOI:10.1038/modpathol.3800712] [PMID]
38. Wu D, Xu J, Yu G, Zhang B, Wang H, Wang C, Ru G, Sun A, Shen L, Wei Q. Expression status of fatty acid synthase (FAS) but not HER2 is correlated with the differentiation grade and prognosis of esophageal carcinoma. Hepato-gastroenterology. 2013 Jan 1;60(121):99-106. [DOI:10.5755/jhqhe.122412]
39. Yoon HH, Shi Q, Sukow WR, Wiktor AE, Khan M, Sattler CA, Grothey A, Wu TT, Diasio RB, Jenkins RB, Sircicope FA. Association of HER2/Erbb2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res. 2012 Jan 15;18(2):546-54. [DOI:10.1158/1078-0432.CCR-11-2272] [PMID] [PMCID]
40. Huang JX, Zhao K, Lin M, Wang Q, Xiao W, Lin MS, et al. HER2 gene amplification in esophageal squamous cell carcinoma is less than in gastroesophageal junction and gastric adenocarcinoma. 2013;6(1):13-8. [DOI:10.3892/cor.2013.1348] [PMID] [PMCID]
41. Barros-Silva JD, Leitao D, Alonso L, Vieira J, Dinis-Ribeiro M, Fragoso M, Bento MJ, Santos L, Ferreira P, Régo S, Brandão C. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer. 2009 Feb;100(3):487-93. [DOI:10.1038/sj.bjc.6604885] [PMID] [PMCID]